Torrent Pharmaceuticals Limited has announced the appointment of Aman Mehta as Managing Director of the company for a period of five years with effect from 1st August, 2025.

Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York. He brings with him a dynamic blend of academic excellence and practical leadership experience across diverse business sectors.

During his 10+ year tenure with Torrent, Aman has held key leadership positions in both the power and pharma verticals of the Group. As an Executive Director at Pharma, Aman has primarily been involved in the India business, Torrent’s largest revenue contributor.

He played an instrumental role in the seamless integration of the Unichem acquisition and the strategic identification and integration of Curatio Healthcare, both of which delivered substantial value and synergies to the company.

Since his appointment as Whole-time Director, Aman has continued to make a significant impact on the company’s growth and transformation journey.

Aman’s contributions as Whole-time Director have been substantial in advancing the company to its next phase of growth. Through a combination of strategic foresight, operational rigor, and people-centric leadership, he continues to play a key role in transforming the company into a more agile, innovative, and globally competitive organization.

His notable contribution to long term sustainable growth for India business are as under: Driving field force expansion from 3,600 MRs in 2022 to 6,400 MRs in FY2025, with year on year improvement in productivity and market share; Turnaround in cardiac portfolio, Torrent’s largest revenue contributor which was earlier marred with legacy portfolio issues; Increase in rank in Diabetes (OAD) TA from 11th to 6th, with an ambition to reach the top 3 in the near future; Portfolio revamp with addition of complex products with large addressable markets in India, with a goal to in first wave of launches; Launching the Consumer Health Division with a focus on 4 key brands that has delivered meaningful growth acceleration; New launch excellence across TAs, achieving top 3 market share ranks in most new launches in the recent past; In-licensing key products as growth levers (empagliflozin, saroglitazar etc.); Turnaround of mature Unichem portfolio to double digit growth and delivering industry leading margins; and Accel

In addition to these contributions, Aman has taken charge of Research & Development and Operations (supply chain & procurement included) functions. Under his leadership R&D has witnessed a sharper alignment with business strategy, emphasizing differentiated product development and accelerated timelines for critical projects; Operational excellence initiatives have been introduced to enhance productivity and cost efficiency across manufacturing and supply chain processes, resulting in tangible improvements in margins and service levels.

Aman’s contributions as Whole-time Director have been substantial in advancing the company to its next phase of growth. Through a combination of strategic foresight, operational rigor, and people-centric leadership, he continues to play a key role in transforming the company into a more agile, innovative, and globally competitive organization.